Company ProfilePremium

Miricor Enterprises Holdings Limited

Company Profile Analysis

Ticker: 1827.HK卓珈控股集團有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Miricor Enterprises Holdings Limited - Company showcase

Year Founded & Workforce

2009

242 Employees

Miricor Enterprises Holdings Limited logo

Miricor Enterprises Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Miricor Enterprises Holdings Limited Overview

Miricor is a small-cap Hong Kong operator of premium non-surgical medical aesthetic and wellness-beauty centres. It is founded, chaired and run by former actress Gigi Lai (Lai Ka Yee Gigi), whose personal brand is central to customer acquisition.

The group runs five treatment centres in Hong Kong's core districts:

  • three CosMax+ medical aesthetic centres (Causeway Bay, Central and Tsim Sha Tsui);

  • two VITAE wellness-beauty centres.

It also sells the Swiss-formulated XOVĒ skincare line through four Hong Kong mall stores and online/mainland channels.

The business is overwhelmingly service-led. Treatment services were 86.9% of FY2025 revenue and medical aesthetics about 89% of FY2026 revenue. It is funded by prepaid treatment packages, with about HK$184m of contract liabilities.

After a failed mainland skincare push in FY2023–FY2024, management retrenched. Since FY2025 it has run a cost-led profit recovery. The company is now debt-free with HK$190m of cash and restored a dividend in FY2026. It is a niche, founder-controlled, cash-rich but shrinking-revenue player in a consolidating, increasingly regulated Hong Kong aesthetics market.


Company's own description. In its filings the group describes itself as principally engaged in two things [RA25; AR25]:

  • providing non-surgical medical aesthetic and wellness beauty services in Hong Kong and Mainland China;

  • selling skincare products.

It reports a single operating segment, "non-surgical medical aesthetic and wellness beauty services". Resources are managed on a unified basis, so no segment P&L is presented. In its corporate governance statement, the company's stated purpose is to become a "powerhouse of Women's Love Brands". It says it does this through customised medical aesthetic and wellness treatments, skincare and cosmetic products, and health supplements [AR25].

Revenue model. Revenue is recognised in four contract-revenue lines [RA25]:

The economic model is a prepaid-package model. Customers purchase treatment courses in advance and revenue is recognised as treatments are consumed. Contract liabilities and deferred revenue were HK$183.7m at 31 March 2025, about 46% of annual revenue [RA25]. This prepayment float largely explains why the group holds substantial cash despite thin profitability. There is no material subscription or licensing income. The group does own its trademarks (XOVĒ, VITAE, CosMax+).

Value-chain position. Miricor sits at the consumer-facing end of the aesthetics value chain:

Upstream: it buys devices, injectables and consumables from third-party manufacturers and distributors. Cost of inventories and consumables was HK$50.4m in FY2025 [RA25].

Doctor-led delivery: treatments are delivered in branded clinics. The company states that all equipment and treatments are clinically evaluated by professional doctors [AR25].

Own skincare brand: XOVĒ is outsourced in formulation, described as backed by a Swiss skincare expert team.

Customer types. The customers are individual retail consumers, predominantly female. The FY2025 MD&A identifies the 20–40 age group as the industry's core demographic, with a rising male share [AR25]. No single customer exceeds 10% of revenue [RA25]. Corporate customers exist but are minor.

End-markets.

  • Hong Kong non-surgical medical aesthetics, about 99% of FY2025 revenue.

  • Hong Kong wellness-beauty services.

  • Premium skincare retail in Hong Kong and, marginally, Mainland China. Mainland revenue was HK$2.8m in FY2025, down from HK$43.4m in FY2024 [RA25].

Independent characterisation. Miricor is best understood as a founder-branded, Hong Kong-centric clinic chain with a capital-light skincare adjunct.

Its competitive moat rests on four things:

  • the celebrity founder's brand equity;

  • prime-location centres;

  • a stock of prepaid customer relationships;

  • a regulatory/medical-safety positioning, reinforced by having former Director of Health Dr. Lam Ping Yan on the board.

Its key weakness is scale. Revenue of HK$362m is roughly 38% of the largest listed Hong Kong peer, Perfect Medical. The group also has a demonstrated inability to make the skincare-retail and mainland expansion strategy pay.

Strategy

Stated strategy (themes from AR25 and the FY2026 results). Management frames strategy around four "core powers": Branding, Customer-Focused, Professionalism and Management Optimisation (品牌力、客戶力、專業力、管理力) [AR25].

  1. Branding: strengthen brand influence and recognition; develop new consumer segments beyond the existing base; use digital marketing and precise customer insights.

  2. Customer-focused: treat existing customers as the core asset; segment retention strategies by spending pattern; design campaigns to deepen brand identification. The loyalty programme was revamped in FY2025.

  3. Professionalism: continuous staff training; introduce innovative, personalised high-end treatments.

  4. Management optimisation: optimise the sales network (i.e., close or relocate weak stores); streamline processes; strengthen digital management systems.

FY2026 additions [FY26-S].

Regulatory positioning: Management expects Hong Kong's stricter regulation of medical devices and practitioners to raise entry barriers, eliminate non-compliant operators and shift share to compliant leaders. It is positioning Miricor as a beneficiary.

Digital transformation: Continued investment in digital operations for customer targeting, conversion and security.

Asset allocation: Systematic introduction of compliant, high-technology-barrier equipment.

Omni-channel skincare: "Online-offline omni-channel integration" for XOVĒ, creating a closed-loop ecosystem for engagement and cross-selling between clinic and retail customers.

Cross-brand synergies: Between CosMax+ and VITAE: store-network efficiency and customer lifecycle management to maximise value per customer.

Initiatives announced in the last 24 months.

Medium-term financial targets and guidance: none publicly disclosed. The company has no stated payout ratio (its dividend policy explicitly has none) [AR25].

Products & Services

Miricor does not publish a priced treatment menu in its filings. Pricing is not publicly disclosed in regulatory documents; retail prices appear only on brand websites and promotions. The catalogue below reflects what has been disclosed in filings and press releases.

CosMax+ (medical aesthetics)

OfferingDescription / capabilitiesTarget customerYear / statusPricing model
Injectables (botulinum toxin, hyaluronic acid fillers)Doctor-administered, minimally invasive wrinkle and volume treatments; identified by management as the leading non-surgical categoryWomen 20–40+, rising male shareOngoingPer-treatment and course packages (prepaid)
Energy-based skin treatments (e.g., photorejuvenation/IPL, picosecond laser)Pigmentation, texture and rejuvenation; "skin management" category highlighted as popular in FY2025Mass-affluent urban consumersOngoing; new devices added in FY2023Course packages
FaceGym™ facial contouringFacial contouring treatment upgraded in November 2022 in response to contouring demandYounger, image-conscious clientsUpgraded Nov 2022—
Medical consultationDoctor consultationsAll clientsOngoingFee per consultation (HK$3,000 of revenue in FY2025)
Prescription and dispensingMedication or prescribed skincare dispensed at centresTreatment clientsOngoingPer item (HK$27,000 of revenue in FY2025)

VITAE (wellness beauty)

OfferingDescriptionTarget customerStatus
Wellness beauty treatmentsHolistic "body, mind and soul" treatments; diversified treatment launches aimed at middle and upper-class consumers (FY2023)Health-conscious middle/upper-class women2 centres (FY2025–FY2026)
Loyalty programmeRevamped in FY2025 to raise retention across brandsExisting clientsRevamped FY2025

XOVĒ (skincare)

Product categoryDescriptionChannel
CleansersFacial cleansingHK stores, e-commerce, mainland platforms
Toners—Same
Serums—Same
Moisturisers—Same
Eye care—Same
UV protectionSunscreen / UV defenceSame
Masks—Same

XOVĒ is positioned as a premium line developed with Swiss skincare experts. It is designed both for daily use and as an adjunct to in-clinic treatments [press release Jun 2023; RA25]. In FY2023 it gained distribution through Sephora in Mainland China [press release Jun 2023]. Whether that arrangement continues is not publicly disclosed. Mainland revenue of HK$2.8m in FY2025 suggests the channel is now immaterial.

Financial Narrative

Miricor presents its P&L by nature of expense. It does not report gross profit, operating income or EBITDA as defined line items. The proxies below are labelled accordingly.

Income statement

Notes on the income statement:

  • Sources: [RA22], [RA23], [RA25], [FY26-S].

  • FY2026 staff, rental and PP&E depreciation figures are derived from the reported changes of −7.9%, −9.0% and −21.7% [FY26-S].

  • FY2022 and FY2023 tax figures are derived as PBT minus profit. FY2023 was a tax credit.

  • FY2021 comparatives: revenue HK$128.9m, PBT −HK$16.2m, loss HK$12.7m, EPS −3.16 cents [RA22].

Margins and EBITDA proxies (derived)

Notes on the EBITDA proxies:

  • Company-defined EBITDA is the chairlady's metric: "earnings before interest on bank loans, taxes and depreciation of PP&E" [AR25].

  • Full EBITDA = PBT + finance costs + PP&E depreciation + ROU depreciation (derived). It flatters the business because ROU depreciation is economically rent.

Revenue CAGR.

  • FY2022–FY2026: −0.1% p.a. (derived).

  • FY2021–FY2026: 23.0% p.a. (derived). This is distorted by the COVID-depressed FY2021 base.

  • FY2024–FY2026, from peak: −14.4% p.a. (derived).

Half-year profile

Notes on the half-year profile:

  • Sources: [IR Sep-2022; IR Sep-2023; IR Sep-2024]. H2 figures are derived as full year minus H1.

  • H1 FY2026 (six months to 30 Sep 2025): company headlines indicate a revenue decline and a small loss. An aggregator shows a period net loss of about HK$0.17m, but its revenue field is internally inconsistent.

Balance sheet

Notes on the balance sheet:

  • Sources: [RA22], [RA23], [IR Sep-2023 comparatives], [RA25], [FY26-S].

  • FY2023 total assets are derived from the 31 Mar 2023 balance-sheet comparatives in IR Sep-2023.

  • FY2022 and FY2023 equity are derived by rolling back FY2024 audited equity using total comprehensive income (no dividends or share issues in the period).

  • FY2021 contract liabilities were HK$168.2m.

  • No goodwill or intangibles appear on the FY2024–FY2025 balance sheets.

Cash flow

Observable facts:

  • Cash and equivalents rose HK$62.5m in FY2025 and HK$8.0m in FY2026. FY2026 also included HK$5.9m of bank-debt repayment.

  • No dividends were paid FY2022–FY2026. The first dividend cash outflow, about HK$40m, falls in FY2027 (October 2026).

  • No share repurchases occurred in FY2025 or FY2026 [RA25; FY26-S].

Ratios (derived)

Notes on the ratios:

  • ROIC is not meaningful. Invested capital is negative once contract liabilities and cash are netted.

  • Net debt/EBITDA is negative (net cash) in all verified years.

  • The cash conversion cycle is structurally misleading for a prepaid-service model. The economically relevant figure is customer prepayments of about HK$184m, which fund the business ahead of service delivery.

Commentary: trends, inflections, drivers

1. Revenue arc (FY2021–FY2026). Revenue followed a COVID trough in FY2021, a reopening boom in FY2022–FY2024, and a two-year decline (FY2025: −18.4%; FY2026: −10.1%).

  • The FY2025 fall was mostly skincare. Skincare fell HK$66.8m (−55.9%) when the mainland push was abandoned. Treatment services declined only 6.5% [RA25].

  • In FY2026 skincare fell a further 24.2% and the core treatment base fell about 8% (derived).

  • This second year of core decline is the more important signal. It tracks weak Hong Kong consumer sentiment and northbound spending by Hong Kong residents.

2. Profit inflection through cost, not growth. FY2025 operating expenses fell 24.5% [AR25]. The main moves were:

  • A&P down 60.3% (HK$65.3m → HK$25.9m);

  • staff costs down 23.0% (headcount 324 → 239);

  • rentals down 20.2%;

  • professional fees down 43.2%.

FY2026 continued the trend: staff −7.9%, rentals −9%, PP&E depreciation −21.7%, A&P −17.7%, professional fees −31.1%, credit-card commission −19.2% [FY26-S]. Net margin recovered from −2.6% (FY2024) to 3.1% (FY2026). The improvement is real but thin, and there is a limit to how far costs can be cut before service capacity suffers.

3. Tax distortion. FY2025 tax of HK$12.4m on PBT of HK$23.0m (54% effective rate) reflected the reversal of deferred tax assets [AR25]. FY2025 pre-tax earnings power was therefore stronger than net profit suggests.

4. Falling depreciation flatters FY2026. PP&E fell from HK$101.1m (FY2023) to HK$50.1m (FY2025). The resulting depreciation decline (−21.7% in FY2026) supports reported profit. It also signals under-investment relative to the FY2022–FY2023 build-out. Future device refresh capex is a monitorable.

5. Balance sheet. Cash of HK$190.3m against zero bank debt is substantial relative to a HK$300m market cap. However:

  • About HK$184m of contract liabilities represent prepaid services owed to customers.

  • Pledged deposits (about HK$66m) back credit-card and bank facilities.

  • "Free" cash is therefore considerably smaller than the headline.

6. Dividend arithmetic. The HK10-cent final dividend costs about HK$40m. That is about 3.6× FY2026 profit (payout about 357%, derived) and about 25% of FY2026 net assets. It is effectively a capital return funded from the cash pile, not a sustainable yield at current earnings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business lineBrandContentsFootprint (latest)

Medical aesthetics

CosMax+

Doctor-supervised non-surgical procedures: injectables (botulinum toxin, hyaluronic acid), energy-based devices (photorejuvenation, picosecond laser), facial contouring

3 centres in Hong Kong core business districts

Wellness beauty

VITAE

Positioned on "a balanced aesthetic experience for body, mind and soul"

2 centres (FY2025, FY2026); 3 in FY2023

Skincare retail

XOVĒ

Swiss-formulated premium skincare: cleanser, toner, serum, moisturiser, eye care, UV protection, masks

4 stores in premium HK malls (FY2026); 3 (FY2025); 10 (Mar 2023); plus e-commerce and mainland platforms

Revenue Lines

Revenue line (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Treatment and medical services (HKD Mn)

289.6333.5374.6350.3322.4

Skincare products (HKD Mn)

74.3129.6119.652.840.0

Total revenue (HKD Mn)

363.9463.1494.3403.2362.4

Revenue by Segment (%) and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Treatment share of revenue (%)

79.672.075.886.989.0

Skincare share of revenue (%)

20.428.024.213.111.0

Treatment YoY growth (%)

—15.212.3-6.5-8.0

Skincare YoY growth (%)

—74.4-7.7-55.9-24.2

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

363.9463.1494.3403.2362.4

Revenue YoY growth (%)

182.327.36.7-18.4-10.1

Cost of inventories and consumables (HKD Mn)

——52.850.4—

Revenue less inventory cost, gross-profit proxy (HKD Mn)

——441.4352.7—

Staff costs (HKD Mn)

——183.8141.6130.4

Property rentals and related expenses (HKD Mn)

——67.954.249.3

Depreciation of PP&E (HKD Mn)

——42.435.027.4

Depreciation of right-of-use assets (HKD Mn)

——50.843.0—

Other expenses net (HKD Mn)

——159.6100.1—

Finance costs (HKD Mn)

——5.25.4—

Operating profit proxy, PBT plus finance costs (HKD Mn)

——-6.628.4—

Profit before tax (HKD Mn)

31.2-23.9-11.823.0—

Income tax expense (HKD Mn)

5.8-3.40.812.4—

Net profit attributable (HKD Mn)

25.4-20.5-12.610.611.2

Basic EPS (HK cents)

6.35-5.13-3.152.652.81

Diluted EPS (HK cents)

6.35-5.13-3.152.652.81

Dividend per share (HK cents)

000010

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%) and Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin proxy (%)

——89.387.5—

Operating margin proxy (%)

——-1.37.0—

PBT margin (%)

8.6-5.2-2.45.7—

Net margin (%)

7.0-4.4-2.62.63.1

Company-defined EBITDA excl. ROU depreciation (HKD Mn)

——31.758.6—

Full EBITDA incl. ROU depreciation, post-HKFRS 16 (HKD Mn)

——86.6106.4—

Full EBITDA margin (%)

——17.526.4—

Income Statement

MetricH1FY2022H2FY2022H1FY2023H2FY2023H1FY2024H2FY2024H1FY2025H2FY2025

Revenue (HKD Mn)

199.7164.2211.9251.2237.0257.3200.1203.1

Net profit (HKD Mn)

53.9-28.53.4-23.9-13.10.4-0.611.2

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (HKD Mn)

—516.8479.4471.3—

Cash and cash equivalents (HKD Mn)

—116.9119.8182.3190.3

Pledged time deposits (HKD Mn)

—62.462.665.8—

Interest-bearing bank borrowings, all current (HKD Mn)

——12.55.90.0

Lease liabilities total (HKD Mn)

——87.282.9—

Net cash excl. leases and pledged deposits (HKD Mn)

——107.3176.5190.3

Contract liabilities and deferred revenue (HKD Mn)

130.2182.0183.0183.7—

Inventories (HKD Mn)

—38.242.235.5—

Property plant and equipment (HKD Mn)

—101.185.850.1—

Right-of-use assets (HKD Mn)

—109.383.178.5—

Goodwill and intangibles (HKD Mn)

——00—

Net current assets / working capital (HKD Mn)

——4.651.1—

Total equity (HKD Mn)

171.3150.7136.8147.6158.3

Key Financials

MetricFY2022FY2023FY2024FY2025FY2026

Change in cash and equivalents (HKD Mn)

——2.962.58.0

Dividends paid (HKD Mn)

00000

Share buybacks (HKD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

16.0-12.7-8.87.47.3

ROA on average assets (%)

——-2.52.2—

Current ratio (x)

——1.021.19—

Bank debt to equity, company gearing (%)

——9.14.00.0

Interest coverage, operating proxy / finance costs (x)

——-1.35.3—

Asset turnover (x)

——0.990.85—

Inventory days on cost of inventories (days)

——291257—

Receivable days (days)

——9.93.5—

Payable days (days)

——7346—

Cash conversion cycle (days)

——228215—

Revenue by Region and Revenue by Region (%)

Region (HKD Mn)FY2024FY2025

Hong Kong revenue (HKD Mn)

450.8400.3

Mainland China revenue (HKD Mn)

43.42.8

Hong Kong share of revenue (%)

91.299.3

Share Price History

DatePrice (HKD)ContextSource

10 Jan 2017

0.80

IPO price

etnet

Jun 2024 (approx.)

1.14

Last-trade snapshot

TradingView

23–26 Jun 2026

0.68

Pre-FY2026 results

lixinger

30 Jun 2026

0.91

Post dividend announcement

lixinger

2–10 Jul 2026

0.90—

lixinger, etnet

14–16 Jul 2026

0.72–0.73

Thin trading

lixinger

17–24 Jul 2026

0.89—

lixinger

27 Jul 2026

0.73—

lixinger

31 Jul – 3 Aug 2026

0.75

Latest verified quote

etnet

Valuation Multiples

MultipleMiricorNotes

Market cap (HKD Mn)

300

400m shares

P/E trailing (x)

26.7

EPS HK2.81 cents

P/B (x)

1.90

Net assets HK$158.3m

EV (HKD Mn)

110

Market cap less cash HK$190.3m; excludes leases and pledged deposits

EV/Sales (x)

0.30—

EV / company-defined EBITDA, FY2025 (x)

1.9

HK$58.6m

Dividend yield (%)

13.3

HK10 cents, likely non-recurring at this level

P/S (x)

0.83—

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (HK cents)

000010

Payout ratio (%)

0000357

Analyst Conclusions

Management guidance. There is no quantitative guidance. Qualitative stance [AR25; FY26-S]:

  • a "prudent and steady" operating strategy;

  • expectation of steady market growth in Hong Kong aesthetics;

  • expectation that regulation will consolidate share toward compliant operators;

  • continued digital investment and equipment upgrades;

  • continued cost discipline.

Consensus. None.

Bull case

  1. Cash-backed downside. EV of only about HK$110m against company-defined EBITDA of HK$58.6m (FY2025) implies about 2× EV/EBITDA for a debt-free business with HK$184m of customer prepayments. The HK10-cent dividend signals the controlling shareholder's willingness to return capital.

  2. Operating leverage. After about HK$90m of annual cost removal between FY2024 and FY2026, any stabilisation of the HK$320–350m treatment base would lift margins sharply.

  3. Regulatory moat. Device and practitioner rules raise the bar. A doctor-led chain with a former Director of Health on the board could gain share or acquire distressed clinics with its cash.

Bear case

  1. Structural shrinkage. Treatment revenue fell in both FY2025 (−6.5%) and FY2026 (about −8%). Cost cuts cannot offset indefinitely, and falling depreciation partly reflects under-investment.

  2. Overstated "free" cash. About HK$184m of contract liabilities and about HK$66m of pledged deposits mean economically unencumbered cash is far smaller than HK$190m. A HK$40m dividend at 3.6× earnings is not repeatable.

  3. Governance and liquidity discount. Combined Chair/CEO, about 69% founder control, no coverage, and a sub-HK$0.5m daily turnover profile. INED tenure has also reached the nine-year threshold. Together these limit any re-rating.

Key catalysts and monitorables (next 12 months)

ItemTiming
Dividend payment and any guidance on future payouts23 Oct 2026
H1 FY2027 interim results (treatment revenue trend, contract-liability balance)Late Nov 2026
Use of share repurchase mandateOngoing
Board refresh and INED replacementsFY2027
Hong Kong medical-device regulation implementation milestones2026–2027
XOVĒ store count and omni-channel resultsFY2027
Capex / device refresh versus depreciationFY2027 accounts
FY2027 results and dividend decisionJun 2027

Analyst verdict

Miricor is a founder-controlled Hong Kong clinic operator that has traded growth for survival, and survival for solvency. The FY2023–FY2024 attempt to turn the company into a skincare-plus-mainland platform failed decisively:

  • record revenue of HK$494m was accompanied by losses;

  • mainland sales collapsed from HK$43m to under HK$3m within a year.

Management deserves credit for the speed and scale of the subsequent restructuring:

  • operating expenses down a quarter in a single year;

  • headcount down by a quarter;

  • bank debt eliminated;

  • two consecutive years of modest profit (HK$10.6m and HK$11.2m).

The resulting balance sheet, with HK$190m of cash and no borrowings, is the stock's defining feature and underpins a superficially compelling valuation of about 0.3× EV/Sales.

That valuation is cheaper than it looks, for three reasons:

  1. Customer prepayments. Much of the cash is customers' money: contract liabilities of about HK$184m are services still owed.

  2. Shrinking core. Two years of decline in treatment revenue show the issue is not just skincare.

  3. Non-recurring dividend. The headline 13% yield rests on a payout roughly 3.6 times earnings. It is better read as a one-off capital return by a 69% holder than as a durable income stream.

Net margins around 3% compare poorly with Perfect Medical's high-teens. This suggests sub-scale economics that cost-cutting alone cannot fix.

The investment debate therefore turns on whether Hong Kong's regulatory tightening produces genuine share consolidation that a compliant, cash-rich, doctor-governed chain can capture, organically or by acquisition. The alternative is a continued slow leak of customers to cheaper cross-border and boutique competitors.

Until the treatment-revenue line stabilises and management articulates a capital-allocation framework, Miricor is best characterised as a special-situation, balance-sheet-supported micro-cap. Its upside depends on capital returns and a regulatory catalyst, not on a growth franchise. Investors should treat it as a liquidity-constrained position, sized accordingly, with the H1 FY2027 contract-liability balance and treatment revenue as the key tells.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAge (AR25)Background / education

Ms. LAI Ka Yee Gigi (黎珈而, formerly Lai Chi, "Gigi Lai")

Executive Director, Chairlady and CEO; Chair of Nomination Committee; member of Remuneration Committee

Joined Jul 2009; Director 6 Jul 2016; Chair/CEO 19 Dec 2016

53 (54 per 2026 AR)

Film and TV actress 1985–2008; founder; responsible for overall management, branding, strategy and marketing

Mr. HO Tsz Leung Lincoln (何子亮)

Executive Director; Chief Operating Officer

Joined Jul 2019 as Chief Brand Officer; ED 22 Apr 2020; COO May 2020

49

Neo Derm Group 2006–2016 and 2017–2019 (marketing communications and digital marketing director); Airport Authority HK (2016); BTL Hong Kong (regional marketing director); DDB, Leo Burnett; BA Design, HK PolyU (2002); 2005 HK Film Awards nominee

Dr. LAM Ping Yan (林秉恩), SBS

Executive Director

Jul 2020

73

Director of Health, HKSAR 2003–2012 (led SARS and swine-flu responses); MBBS HKU (1977); MMed Public Health NUS (1992); FHKAM; former member of Medical Council of HK and Hospital Authority Board

Mr. CHENG Yuk Wo (鄭毓和)

INED; Chair of Audit and Remuneration Committees

19 Dec 2016

64

Chartered accountant (ICAEW, HKICPA, CPA Canada); MSc LSE; INED of CSI Properties, Liu Chong Hing Investment, Chia Tai Enterprises, Somerley Capital, Kidsland

Mr. CHENG Fu Kwok David (鄭輔國)

INED; Audit and Nomination Committees

19 Dec 2016

76

Former Head of Shipfinance, Crédit Agricole CIB; Chevalier de l'Ordre National du Mérite (2015); BSocSc HKU

Mr. LI Wai Kwan (李偉君)

INED; Audit and Remuneration Committees

19 Dec 2016

53

CFO of Crystal International Group (2232.HK) since Nov 2018; formerly Esprit, COFCO; CFA, FCCA, FCA; BCom Toronto, MBA Schulich

Major Shareholders

HolderShares%Basis

Sunny Bright Group Holdings Ltd (BVI), beneficially associated with Ms. Lai Ka Yee Gigi and spouse Mr. Ma Ting Keung (馬廷強)

275,000,00068.75

etnet SDI data (30 Sep 2024); listing documents

Meitu, Inc. (1357.HK)

about 20,000,000 (implied)

5.0

Newswire brief of an HKEX filing that Meitu's long position "rose to 5.0%".

Public float

about 125,000,000

about 31.25

Derived

Shareholding by CCASS Participant

CCASS participantShares (m)%

Bank of East Asia (custodian of the controlling block)

275.068.75

Bright Smart Securities

37.79.42

UOB Kay Hian (HK)

20.05.00

UBS

19.44.85

BOCI Securities

11.02.74

華晉證券資產管理

7.01.74

威華達證券

6.11.53

Competitive Landscape

Key Competitors

CompetitorListingPositioning vs MiricorLatest revenueSource

Perfect Medical Health Management

1830.HK

Largest listed HK medical-beauty chain; multi-brand; 100%+ payout policy

HK$962.3m (FY3/2026, −14.7%); profit HK$178.3m

Perfect Medical results announcement, 30 Jun 2026

Water Oasis Group (Oasis Medical, Oasis Beauty, Glycel, Eurobeauté, AesMedic)

1161.HK

Integrated beauty services and products; 9 Oasis Medical centres

About HK$981m (FY9/2025); earnings about HK$81m

Water Oasis AR 2025; stockanalysis.com (secondary)

EC Healthcare (medical aesthetics within a broader healthcare platform)

2138.HK

Scale player, medical-led

——

Neo Derm Group

Private

Medical aesthetics chain; COO Ho's former employer

——

DR Reborn

Private

Mass-premium beauty/aesthetics chain

——

Modern Beauty Salon

—

Beauty salons/spa

——

Independent doctor-led aesthetic clinics

Private

Fragmented long tail; price competitors

——

Mainland "northbound" aesthetics (Shenzhen clinics)

Various

Cheaper treatments for HK residents crossing the border

Not quantified

—

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricMiricor (FY3/2026)Perfect Medical (FY3/2026)Water Oasis (FY9/2025)

Revenue (HKD Mn)

362.4962.3981.3

Revenue growth YoY (%)

-10.1-14.7-0.2

Net profit (HKD Mn)

11.2178.381.3

Net margin (%)

3.118.58.3

Dividend payout (%)

357102.8—

Miricor revenue as % of peer (%)

10037.736.9

Company Snapshot

$46.5M

Revenue

242

Employees

$38M

Market Cap

2009

Founded

Central, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Net-cash balance sheet. Cash of HK$190.3m and zero bank borrowings at 31 March 2026 [FY26-S], versus a market cap of about HK$300m.
  • Prepaid revenue visibility. Contract liabilities of HK$183.7m (45.6% of FY2025 revenue) [RA25].
  • Demonstrated cost discipline. FY2025 opex −24.5%; A&P −60.3%; staff costs −23.0% [AR25]. FY2026 staff −7.9%, rentals −9% [FY26-S].
  • Resilient core. Treatment services fell only 6.5% in FY2025 while skincare fell 55.9% [RA25].
  • Medical-governance credentials. Dr. Lam Ping Yan, former Director of Health (2003–2012), is on the board [AR25]. This is useful as regulation tightens.
  • Founder brand. A&P of only 7.2% of revenue (FY2025) sustains a HK$350m treatment business [AR25].

Weaknesses

  • Shrinking top line. Revenue fell 26.7% from the FY2024 peak (HK$494.3m) to FY2026 (HK$362.4m).
  • Thin margins. Net margin of 3.1% (FY2026) versus about 18.5% at Perfect Medical (derived).
  • Failed diversification. Mainland revenue went from HK$43.4m to HK$2.8m and XOVĒ stores from 10 to 4. Heavy FY2024 A&P (HK$65.3m) yielded a loss [RA25; AR25].
  • Governance gaps. Combined Chair/CEO (C.2.1 deviation); no in-house internal audit; all INEDs at or above nine years' tenure [AR25].
  • Illiquid stock. About 31% free float, with frequent zero-volume days; large single-day price swings (HK$0.73 → HK$0.89 → HK$0.73 in July 2026) [MKT].
  • Earnings quality. FY2026 profit is helped by depreciation falling 21.7% as PP&E fell from HK$101.1m (FY2023) to HK$50.1m (FY2025). This suggests reduced reinvestment [RA25; FY26-S].

Opportunities

  • Regulatory consolidation. Stricter device and practitioner rules could eliminate non-compliant operators [FY26-S].
  • Capital deployment. About HK$190m of cash could fund bolt-on acquisitions of distressed small clinics, or buybacks under the AGM repurchase mandate (Jul 2026 notice).
  • Cross-selling. Omni-channel integration of XOVĒ with the clinic base [FY26-S].
  • Demographic tailwinds. A younger and male consumer cohort is entering aesthetics [AR25].
  • Operating leverage. Any revenue recovery would flow through to profit after two years of cost cuts.
  • Tourism. Inbound visitor demand for prime-district (TST Harbour City) centres.

Threats

  • Northbound leakage. Hong Kong consumers increasingly purchase services in Shenzhen. This is an inference from industry trend; Miricor-specific impact is not disclosed.
  • Price competition. Low-cost clinic entrants; management notes "mushrooming" small and mid-size institutions [AR25].
  • Prepaid-package consumer protection. Any regulatory tightening or business failure in the industry raises scrutiny of prepaid models. Miricor's HK$184m liability is material relative to its equity of HK$158m.
  • Medical-incident risk. A single adverse event could damage both brand and licence.
  • Key-person risk. The founder (age 54) is Chair, CEO and controlling shareholder.
  • Rent and lease risk. Leases of HK$82.9m (FY2025) in prime districts.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 Nov 2024Profit warning (positive): H1 FY2025 loss expected at HK$0.5–1.5m vs HK$13.05mFirst signal of the cost-led turnaround
29 Nov 2024H1 FY2025 results: revenue HK$200.1m (−15.6%); loss HK$0.63mTurnaround confirmed; staff costs −19%
6 Jun 2025Positive profit alert: FY2025 profit expected of at least about HK$10mSwing to profit flagged
25 Jun 2025FY2025 results: revenue HK$403.2m (−18.4%); profit HK$10.6m; no dividendReturn to profitability
25 Jun 2025Board approves FY2025 audited accounts; four board meetings held in yearGovernance routine
24 Jul 2025Annual Report 2025 published: headcount 239; gearing 4.0%; EY fee HK$1.6mDisclosure
Jul 2025Monthly returns (securities movements) filed monthly through 2026No share-capital changes
17 Sep 2025Simply Wall St note critical of CEO compensationGovernance optics
22 Sep 2025AGM postponed due to typhoonOperational
29 Sep 2025AGM resolutions passed unanimouslyRoutine; director re-elections
Nov 2025Board meeting notice for interim resultsRoutine
25 Nov 2025Core revenue still contracting
29 Jan 2026Simply Wall St note on improving ROCE trajectoryMarket narrative turning to efficiency
Jan–Jun 2026Monthly returns filed; no issuance or buybackCapital stability
15 Jun 2026Board meeting date announcementRoutine
23–26 Jun 2026Share price about HK$0.68 ahead of resultsPre-results base
26 Jun 2026FY2026 results: revenue HK$362.4m (−10.1%); profit HK$11.2m (+5.7%); EPS 2.81 cents; cash HK$190.3m; borrowings nil; net assets HK$158.3mProfit up on lower revenue; balance sheet ungeared
26 Jun 2026First-ever final dividend: HK10 cents per shareMajor capital-return signal (about HK$40m)
26 Jun 2026FY2026 skincare revenue −24.2% to HK$40.0m; medical aesthetics about 89% of revenueSkincare still shrinking
26 Jun 2026Impairments: PP&E HK$0.575m; right-of-use HK$1.793mOngoing site pruning
26 Jun 2026Management highlights Hong Kong medical-device and practitioner regulation as industry-consolidatingStrategic narrative
30 Jun 2026Shares jump to about HK$0.91 after the dividend announcementRe-rating on yield
2 Jul 2026Monthly return for June 2026Routine
14–31 Jul 2026Shares fall back to HK$0.72–0.75 in thin tradingIlliquidity; yield not fully priced
23 Jul 2026Annual Report 2025/26; AGM notice; general mandates to issue and repurchase shares; re-election of retiring directors; reappointment of auditorRoutine; repurchase mandate is optionality
18 Sep 20262026 AGM held, chaired by Lai–
24–30 Sep 2026Register closure; record date 30 Sep 2026Dividend entitlement
23 Oct 2026Scheduled dividend paymentAbout HK$40m cash outflow

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 363.9 Mn in FY2022 to HKD 362.4 Mn in FY2026.
Miricor Enterprises Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue363.9463.1494.3403.2362.4
Cost of inventories and consumables——52.850.4—
Revenue less inventory cost, gross-profit proxy——441.4352.7—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. HKEX: FY2025 Annual Results Announcement (Chinese), 25 Jun 2025 — hkexnews.hk/listedco/listconews/sehk/2025/0625/2025062501693_c.pdf
  2. HKEX: Annual Report 2025, 24 Jul 2025 — hkexnews.hk/listedco/listconews/sehk/2025/0724/2025072400921.pdf
  3. HKEX: FY2023 Annual Results Announcement, 26 Jun 2023 — www1.hkexnews.hk/listedco/listconews/sehk/2023/0626/2023062601164.pdf
  4. HKEX: FY2022 Annual Results Announcement, 24 Jun 2022 — www1.hkexnews.hk/listedco/listconews/sehk/2022/0624/2022062401334.pdf
  5. HKEX: Interim results announcements for H1 FY2023 (25 Nov 2022), H1 FY2024 (24 Nov 2023) and H1 FY2025 (29 Nov 2024)
  6. HKEX: Profit warnings / alerts of 22 Nov 2024 and 6 Jun 2025
  7. HKEX: Transfer of listing announcements, 1 Jun 2018 and 8 Feb 2019 · GEM listing form (initial listing 10 Jan 2017)
  8. HKEX: Voluntary announcement on Harbour City lease, 16 Mar 2018; supplemental discloseable transaction on Soundwill Plaza lease, 20 Oct 2021
  9. FY2026 results summaries: Minichart (27 Jun 2026) · Tiger Brokers / Stock News (26 Jun 2026); etnet announcements list; hstong.com (dividend payment date)
  10. Company press releases via EQS/DLK Advisory, 26 and 29 Jun 2023: ACN Newswire, 13 Feb 2017
  11. Market data: etnet.com.hk quotes (Jul–Aug 2026); lixinger.com valuation and CCASS data (Jul 2026) · Morningstar company profile
  12. Peers: Perfect Medical FY2026 results announcement (30 Jun 2026) and AR 2025/26 · Water Oasis AR 2025 and stockanalysis.com (WOSSF)
  13. News: rccaijing.com (22 Sep 2026 AGM report) · MT Newswires/Tiger (Dec 2024) · TipRanks and Longbridge headline feeds · Stockopedia news briefs (Meitu stake, historical briefs)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.